Rare diseases
Investigational molecules
Locations
Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)
AustriaStudy on the Effectiveness and Safety of Alpelisib for Patients with Dent 2 Disease
ItalyStudy on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer
NorwayStudy on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients
PortugalStudy on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma
The NetherlandsStudy on Alpelisib for Treating Lymphatic Malformations in Patients with PIK3CA Mutation
BelgiumStudy on the Effects and Safety of Alpelisib for Children and Adults with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome
FranceStudy on Alpelisib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer
CroatiaStudy of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation
FranceGedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy
AustriaStudy of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)
FranceStudy on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors
The NetherlandsTell us about your condition – we search every trial in Europe and connect you with the right site.
